<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01181271</url>
  </required_header>
  <id_info>
    <org_study_id>10-057</org_study_id>
    <nct_id>NCT01181271</nct_id>
  </id_info>
  <brief_title>Tandem Auto-Allo Transplant for Lymphoma</brief_title>
  <official_title>Sequential Myeloablative Autologous Stem Cell Transplantation Followed by Allogeneic Non-Myeloablative Stem Cell Transplantation for Patients With Poor Risk Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Relapse remains a principle cause of treatment failure for patients with aggressive lymphoma
      after autologous transplantation. Non-myeloablative allogeneic transplantation allows
      patients to receive an infusion of donor cells in an attempt to induce a graft versus
      lymphoma effect. This study will assess the feasibility, safety and efficacy of the
      combination of autologous stem cell transplantation followed by non-myeloablative
      transplantation for patients with poor-risk aggressive lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase II clinical trial investigating the feasibility, and efficacy of sequential
      autologous stem cell transplant followed by non-myeloablative allogeneic transplant for
      patients with poor risk lymphoma. Patients will be enrolled onto the trial when eligible and
      undergo standard high-dose chemotherapy with the combination with busulfan, cyclophosphamide,
      and etoposide followed by autologous stem cell transplant. After recovery of counts and
      clinical status, patients will then proceed to non-myeloablative allogeneic stem cell
      transplant using a fully matched related or unrelated donor.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peripheral Blood All-cell Donor Chimerism</measure>
    <time_frame>100 days post allogeneic transplant</time_frame>
    <description>Successful donor stem cell engraftment is defined as when â‰¥ 80% of hematopoietic elements are donor-derived as determined by chimerism assays from peripheral blood at day 100 after non-myeloablative allogeneic stem cell transplantation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Days After Allogeneic Transplant Until Absolute Neutrophil Count Was Equal to or Greater Than 500/uL</measure>
    <time_frame>within 28 days after allogeneic transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Incidence of Grades II to IV Acute Graft Versus Host Disease (GVHD)</measure>
    <time_frame>within 200 days after allogeneic transplant</time_frame>
    <description>Grade I GVHD is characterized as mild disease, grade II GVHD as moderate, grade III as severe, and grade IV life-threatening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Incidence of Extensive Chronic Graft-versus-host-disease</measure>
    <time_frame>1-year after allogeneic transplant</time_frame>
    <description>Extensive chronic graft versus-host-disease (GVHD) was defined as GVHD that required systemic immunosuppression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Incidence of Non-relapse Mortality</measure>
    <time_frame>2-years after allogeneic transplant</time_frame>
    <description>Non-relapse mortality is defined as participants who die from causes other than their underlying disease relapse, such as infection or graft versus host disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Incidence of Disease Relapse</measure>
    <time_frame>2-years after allogeneic transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Two Year Progression Free Survival Rate for Participants Undergoing Both Autologous and Allogeneic Transplants</measure>
    <time_frame>2 years after allogeneic transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Two Year Overall Survival Rate for Participants Undergoing Both Autologous and Allogeneic Transplants</measure>
    <time_frame>Two-years after Allogeneic Transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Two Year Progression Free Survival Rate for All Participants</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Two Year Overall Survival Rate for All Participants</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Two Year Progression Free Survival Rate for Participants Undergoing Only Autologous Transplant</measure>
    <time_frame>Two Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Two Year Overall Survival Rate for Participants Undergoing Only Autologous Transplant</measure>
    <time_frame>two years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Diffuse, Large B-Cell, Lymphoma</condition>
  <condition>Lymphoma, Low-Grade</condition>
  <condition>T-Cell Lymphoma</condition>
  <condition>Mantle-Cell Lymphoma</condition>
  <condition>Hodgkin's Lymphoma</condition>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Lymphoma, Small Lymphocytic</condition>
  <arm_group>
    <arm_group_label>Autologous then Allogeneic transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive conditioning with busulfan, etoposide, and cyclophosphamide (with mesna) and then will undergo autologous (auto) peripheral blood stem cell transplantation.
Patients will be re-evaluated after autologous transplant prior to proceeding to non-myeloablative allogeneic (allo) transplant. If eligible to proceed, allogenic transplantation will take place no earlier than 40 days and no later than 180 days after autologous stem cell transplantation.
Conditioning for the allogeneic transplant will consist of fludarabine and busulfan. Participants will receive tacrolimus and sirolimus as prophylaxis against graft versus host disease (GVHD).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan (conditioning for AUTO transplant)</intervention_name>
    <description>0.8 mg/kg intravenous (IV) bolus every six hours (Q6H) on days -8,-7,-6,-5 (total of 14 doses). The total daily dose of busulfan will be 3.2 mg/kg on days -8,-7, and -6 and 1.6 mg/kg on day -5</description>
    <arm_group_label>Autologous then Allogeneic transplant</arm_group_label>
    <other_name>Busulfex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide (conditioning for AUTO transplant)</intervention_name>
    <description>Etoposide 30 mg/kg IV bolus every day (QD) on day -4. The total daily dose of etoposide will be 30 mg/kg.</description>
    <arm_group_label>Autologous then Allogeneic transplant</arm_group_label>
    <other_name>VP-16</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide (conditioning for AUTO transplant)</intervention_name>
    <description>Cyclophosphamide 60 mg/kg IV bolus QD on days -3 and -2. The total daily dose of cyclophosphamide will be 60 mg/kg.</description>
    <arm_group_label>Autologous then Allogeneic transplant</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesna (prior to AUTO transplant)</intervention_name>
    <description>Mesna 15 mg/kg IV bolus on days -3 and -2 infused over 15 minutes and given 15 minutes prior to cyclophosphamide administration. This is followed by Mesna given 15 mg/kg IV bolus three times daily (TID) on days -3 and -2 infused over 15 minutes at 3, 6, and 9 hours after completion of cyclophosphamide infusion. Total daily dose of Mesna should be equivalent to daily dose of cyclophosphamide. Lastly, Mesna will be given at 15 mg/kg IV bolus QD on day -1. This makes a total of 9 doses of Mesna</description>
    <arm_group_label>Autologous then Allogeneic transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>autologous (auto) peripheral blood stem cell transplantation</intervention_name>
    <description>Infusion of autologous peripheral blood stem cells on Day 0.</description>
    <arm_group_label>Autologous then Allogeneic transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neupogen</intervention_name>
    <description>Neupogen 5 mcg/kg subcutaneous (SQ) daily starting on day +1 until absolute neutrophil count (ANC) is greater than or equal to 1000 per micro liter on two separate occasions or greater than 5000 per micro liter once</description>
    <arm_group_label>Autologous then Allogeneic transplant</arm_group_label>
    <other_name>G-CSF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine (conditioning for ALLO Transplant)</intervention_name>
    <description>Fludarabine 30 mg/m2/day will be administered as a bolus infusion over approximately 30 minutes for 4 days on days -5, -4, -3, -2.</description>
    <arm_group_label>Autologous then Allogeneic transplant</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan (conditioning for ALLO Transplant)</intervention_name>
    <description>Busulfan will be administered by IV infusion over approximately 3 hours on days -5, -4, -3, -2. The dose of busulfan will be 0.8 mg/kg/day</description>
    <arm_group_label>Autologous then Allogeneic transplant</arm_group_label>
    <other_name>Busulfex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>non-myeloablative allogeneic (allo) transplant</intervention_name>
    <description>Donor peripheral blood stem cells (PBSC) will be infused intravenously beginning on Day 0. The minimum total CD34+ cell dose will be 2 x 10^6 CD34+cells/kg of recipient's actual body weight with a maximum dose of 8 x 10^6/kg of recipient's actual body weight</description>
    <arm_group_label>Autologous then Allogeneic transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Tacrolimus (FK506) will be given orally at a dose of 0.05 mg/kg orally (PO) twice a day (BID) starting day -3.</description>
    <arm_group_label>Autologous then Allogeneic transplant</arm_group_label>
    <other_name>FK506</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>Sirolimus (rapamycin) will be given orally at a dose of 12 mg times one on day -3 and then the dose shall be 4 mg by mouth daily starting on day -2. The dose may then be adjusted according to serum levels at the discretion of the treating physician</description>
    <arm_group_label>Autologous then Allogeneic transplant</arm_group_label>
    <other_name>Rapamycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Methotrexate will be administered once daily on days 1, 3, and 6 as an IV bolus over 15 minutes at a dose of 5 mg/m2</description>
    <arm_group_label>Autologous then Allogeneic transplant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with high-risk diffuse large B cell or transformed low grade lymphoma defined
             as:

               -  Residual disease after at least 6 cycles of anthracycline-based chemotherapy
                  (with residual disease defined as persistent bone marrow involvement and/or
                  persistent measurable lymph node or solid organ masses that are PET or gallium
                  avid)

               -  Progressive disease after at least 2 cycles of anthracycline-based chemotherapy

               -  Patients with an initial complete response but subsequent relapse within 6 months
                  after completion of anthracycline-based chemotherapy

          -  Patients with any T-cell non-Hodgkin's lymphoma as defined as:

               -  Peripheral T-cell lymphoma (ALK negative PTCL-U) including PTCL-NOS, HSGD
                  (hepato-splenic gamma-delta TCL), AITL (angioimmunoblastic T-cell lymphoma), EATL
                  (enteropathy associated T-cell lymphoma), ALK-negative anaplastic large cell
                  lymphoma

               -  Any T-cell histology (except LGL) with residual disease after at least 4 cycles
                  of anthracycline-based chemotherapy (with residual disease defined as persistent
                  bone marrow involvement and/or persistent measurable lymph node or solid organ
                  masses that are PET or gallium avid)

          -  Patients with mantle cell lymphoma at any time in therapy

          -  Patients with &quot;double-hit&quot; lymphoma as characterized by the presence of concurrent
             overexpression of Bcl-2 and c-myc

          -  Patients with Hodgkin's lymphoma that is

               -  Refractory to first-line therapy and at least one second line chemotherapy
                  regimen

               -  Relapsed Hodgkin's lymphoma which is refractory to at least one salvage
                  chemotherapy regimen.

          -  Patients with CLL/SLL with 17p- cytogenetic abnormality

          -  Age 18 years and greater

          -  ECOG performance status 0-2

          -  Ability to understand and the willingness to sign a written informed consent document.

          -  Responsive disease to last therapy as determined by at least one of the following:

               -  At least PR by Revised Response Criteria

               -  At least PR by traditional Cheson Criteria

               -  &lt; 10% of overall cellularity involved with disease on bone marrow biopsy for
                  patients with involvement of the bone marrow

          -  Minimum of 2 x 106 CD34+ cells / kg already collected and frozen. These stem cells may
             have been collected from PBSC pheresis, bone marrow harvest, or the combination.

        Exclusion Criteria:

        Patients will be re-evaluated after autologous transplant prior to proceeding to
        non-myeloablative transplant

          -  Pregnancy

          -  Evidence of HIV infection

          -  Heart failure uncontrolled by medications or ejection fraction less than 45%

          -  Active involvement of the CNS by lymphoma

          -  Inability to provide informed consent

          -  Previous autologous or allogeneic stem cell transplant

          -  Creatinine greater than 2 gm/dL or 24 hour urine creatinine clearance &lt; 50 cc/minute
             (does not have to satisfy both)

          -  Total bilirubin greater than 2 times the upper limit of normal except when due to
             Gilbert's syndrome or hemolysis.

          -  Transaminases greater than 3 times the upper limit of normal

          -  FVC or DLCO of less than 50% of predicted (DLCO corrected for hemoglobin level)

          -  Already known to not possess suitably HLA-matched related or unrelated donor

        Eligibility to proceed to allogeneic transplant Cannot be admitted for allogeneic
        transplant earlier than 40 days and no later than 180 days after autologous stem cell
        transplant.

          -  HLA identical (A, B, C and DR) related or unrelated donor available. HLA typing of
             class I loci (HLA- A, B, C) will be based on complement dependent cytotoxicity assay
             or PCR of sequence specific oligonucleotide primers (SSOP). Typing of HLA class II
             (DRB1) will be based on PCR of sequence specific oligonucleotide primers (SSOP).

          -  No need for intravenous hydration in the previous 2 weeks

          -  Resolved mucositis

          -  Renal, cardiac, pulmonary, and hepatic function meet standard criteria for
             nonmyeloablative SCT as listed below:

               -  Serum Cr &lt; 2 gm/dL

               -  LV ejection fraction &gt; 30% and no uncontrolled symptoms of congestive heart
                  failure

               -  DLCO &gt; 50% of predicted value (corrected for hemoglobin)

               -  Transaminases &lt; 5X the institution upper limit of normal

               -  Bilirubin &lt; 3X the institution upper limit of normal except when Gilbert's
                  Syndrome or hemolysis is present

               -  ECOG PS â‰¤ 2

          -  No intravenous antimicrobials within 2 weeks

          -  No evidence of progressive disease, defined as a 25% increase from nadir in the sum of
             the product of the diameters (SPD) of any lymph node previously identified as abnormal
             prior to autologous transplant or the appearance of any new lymph node greater than
             1.5 cm in greatest diameter, new bone marrow involvement, or new solid organ nodule
             greater than 1 cm in diameter. This restaging study will be performed at least 28 days
             after the autologous transplant and within 60 days prior to admission for allogeneic
             transplant. Status of stable disease (SD) is acceptable to proceed to allogeneic
             transplant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yi-Bin A Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Chen YB, Li S, Fisher DC, Driscoll J, Del Rio C, Abramson J, Armand P, Barnes J, Brown J, Cutler C, El-Jawahri A, Ho VT, Hochberg E, McAfee S, Takvorian R, Spitzer TR, Antin JH, Soiffer R, Jacobsen E. Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma. Biol Blood Marrow Transplant. 2015 Sep;21(9):1583-8. doi: 10.1016/j.bbmt.2015.05.016. Epub 2015 May 22.</citation>
    <PMID>26009261</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2010</study_first_submitted>
  <study_first_submitted_qc>August 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2010</study_first_posted>
  <results_first_submitted>January 19, 2017</results_first_submitted>
  <results_first_submitted_qc>January 19, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 9, 2017</results_first_posted>
  <last_update_submitted>January 19, 2017</last_update_submitted>
  <last_update_submitted_qc>January 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Yi-Bin A. Chen, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Lymphoma</keyword>
  <keyword>non-hodgkins lymphoma</keyword>
  <keyword>Hodgkin's lymphoma</keyword>
  <keyword>Hodgkin's disease</keyword>
  <keyword>stem cell transplant</keyword>
  <keyword>High-risk diffuse large B cell</keyword>
  <keyword>Transformed low grade lymphoma</keyword>
  <keyword>T-cell non-Hodgkin's lymphoma</keyword>
  <keyword>Mantle cell lymphoma at any time in therapy</keyword>
  <keyword>&quot;Double-hit&quot; lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Allopurinol</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Mesna</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled between October 2010 and June 2013.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Autologous Then Allogeneic Transplant</title>
          <description>Autologous, then Allogeneic Stem Cell Transplantation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Autologous Transplant</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Evaluation for Allogeneic Transplant</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No suitable donor</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>therapy-related AML diagnosed</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Allogeneic Transplant</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Autologous Then Allogeneic Transplant</title>
          <description>Autologous then allogeneic stem cell transplantation</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.5" lower_limit="22" upper_limit="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior lines of chemotherapy</title>
          <units>lines</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2" lower_limit="1" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diagnosis</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Relapsed/refractory Diffuse Large B-cell Lymphoma</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Relapsed/refractory Non-Hodgkin Lymphoma</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Double-Expressing Non-Hodgkin Lymphoma</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Transformed B-cell Non-Hodgkin Lymphoma</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>T-cell Non-Hodgkin Lymphoma</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mantle cell Non-Hodgkin Lymphoma</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Relapsed/Refractory Hodgkin Lymphoma</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Heavy chain disease</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Disease status at study entry</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Partial Response</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Complete Response</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Peripheral Blood All-cell Donor Chimerism</title>
        <description>Successful donor stem cell engraftment is defined as when â‰¥ 80% of hematopoietic elements are donor-derived as determined by chimerism assays from peripheral blood at day 100 after non-myeloablative allogeneic stem cell transplantation.</description>
        <time_frame>100 days post allogeneic transplant</time_frame>
        <population>Participants who underwent the full tandem AUTO-ALLO stem cell transplant</population>
        <group_list>
          <group group_id="O1">
            <title>Autologous Then Allogeneic Transplant</title>
            <description>All patients will receive conditioning with busulfan, etoposide, and cyclophosphamide (with mesna) and then will undergo autologous (auto) peripheral blood stem cell transplantation.
Patients will be re-evaluated after autologous transplant prior to proceeding to non-myeloablative allogeneic (allo) transplant. If eligible to proceed, allogenic transplantation will take place no earlier than 40 days and no later than 180 days after autologous stem cell transplantation.
Conditioning for the allogeneic transplant will consist of fludarabine and busulfan. Participants will receive tacrolimus and sirolimus as prophylaxis against graft versus host disease (GVHD).</description>
          </group>
        </group_list>
        <measure>
          <title>Peripheral Blood All-cell Donor Chimerism</title>
          <description>Successful donor stem cell engraftment is defined as when â‰¥ 80% of hematopoietic elements are donor-derived as determined by chimerism assays from peripheral blood at day 100 after non-myeloablative allogeneic stem cell transplantation.</description>
          <population>Participants who underwent the full tandem AUTO-ALLO stem cell transplant</population>
          <units>percentage of donor-derived elements</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="83" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days After Allogeneic Transplant Until Absolute Neutrophil Count Was Equal to or Greater Than 500/uL</title>
        <time_frame>within 28 days after allogeneic transplant</time_frame>
        <population>This was only measured in the 17 participants who experienced a hematological nadir after allo transplant.</population>
        <group_list>
          <group group_id="O1">
            <title>Autologous Then Allogeneic Transplant</title>
            <description>All patients will receive conditioning with busulfan, etoposide, and cyclophosphamide (with mesna) and then will undergo autologous (auto) peripheral blood stem cell transplantation.
Patients will be re-evaluated after autologous transplant prior to proceeding to non-myeloablative allogeneic (allo) transplant. If eligible to proceed, allogenic transplantation will take place no earlier than 40 days and no later than 180 days after autologous stem cell transplantation.
Conditioning for the allogeneic transplant will consist of fludarabine and busulfan. Participants will receive tacrolimus and sirolimus as prophylaxis against graft versus host disease (GVHD).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days After Allogeneic Transplant Until Absolute Neutrophil Count Was Equal to or Greater Than 500/uL</title>
          <population>This was only measured in the 17 participants who experienced a hematological nadir after allo transplant.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="1" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Incidence of Grades II to IV Acute Graft Versus Host Disease (GVHD)</title>
        <description>Grade I GVHD is characterized as mild disease, grade II GVHD as moderate, grade III as severe, and grade IV life-threatening.</description>
        <time_frame>within 200 days after allogeneic transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Autologous Then Allogeneic Transplant</title>
            <description>All patients will receive conditioning with busulfan, etoposide, and cyclophosphamide (with mesna) and then will undergo autologous (auto) peripheral blood stem cell transplantation.
Patients will be re-evaluated after autologous transplant prior to proceeding to non-myeloablative allogeneic (allo) transplant. If eligible to proceed, allogenic transplantation will take place no earlier than 40 days and no later than 180 days after autologous stem cell transplantation.
Conditioning for the allogeneic transplant will consist of fludarabine and busulfan. Participants will receive tacrolimus and sirolimus as prophylaxis against graft versus host disease (GVHD).</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Incidence of Grades II to IV Acute Graft Versus Host Disease (GVHD)</title>
          <description>Grade I GVHD is characterized as mild disease, grade II GVHD as moderate, grade III as severe, and grade IV life-threatening.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8" lower_limit="5.3" upper_limit="26.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Incidence of Extensive Chronic Graft-versus-host-disease</title>
        <description>Extensive chronic graft versus-host-disease (GVHD) was defined as GVHD that required systemic immunosuppression.</description>
        <time_frame>1-year after allogeneic transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Autologous Then Allogeneic Transplant</title>
            <description>All patients will receive conditioning with busulfan, etoposide, and cyclophosphamide (with mesna) and then will undergo autologous (auto) peripheral blood stem cell transplantation.
Patients will be re-evaluated after autologous transplant prior to proceeding to non-myeloablative allogeneic (allo) transplant. If eligible to proceed, allogenic transplantation will take place no earlier than 40 days and no later than 180 days after autologous stem cell transplantation.
Conditioning for the allogeneic transplant will consist of fludarabine and busulfan. Participants will receive tacrolimus and sirolimus as prophylaxis against graft versus host disease (GVHD).</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Incidence of Extensive Chronic Graft-versus-host-disease</title>
          <description>Extensive chronic graft versus-host-disease (GVHD) was defined as GVHD that required systemic immunosuppression.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.9" lower_limit="23.1" upper_limit="52.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Incidence of Non-relapse Mortality</title>
        <description>Non-relapse mortality is defined as participants who die from causes other than their underlying disease relapse, such as infection or graft versus host disease</description>
        <time_frame>2-years after allogeneic transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Autologous Then Allogeneic Transplant</title>
            <description>All patients will receive conditioning with busulfan, etoposide, and cyclophosphamide (with mesna) and then will undergo autologous (auto) peripheral blood stem cell transplantation.
Patients will be re-evaluated after autologous transplant prior to proceeding to non-myeloablative allogeneic (allo) transplant. If eligible to proceed, allogenic transplantation will take place no earlier than 40 days and no later than 180 days after autologous stem cell transplantation.
Conditioning for the allogeneic transplant will consist of fludarabine and busulfan. Participants will receive tacrolimus and sirolimus as prophylaxis against graft versus host disease (GVHD).</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Incidence of Non-relapse Mortality</title>
          <description>Non-relapse mortality is defined as participants who die from causes other than their underlying disease relapse, such as infection or graft versus host disease</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" lower_limit="3.5" upper_limit="23.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Incidence of Disease Relapse</title>
        <time_frame>2-years after allogeneic transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Autologous Then Allogeneic Transplant</title>
            <description>All patients will receive conditioning with busulfan, etoposide, and cyclophosphamide (with mesna) and then will undergo autologous (auto) peripheral blood stem cell transplantation.
Patients will be re-evaluated after autologous transplant prior to proceeding to non-myeloablative allogeneic (allo) transplant. If eligible to proceed, allogenic transplantation will take place no earlier than 40 days and no later than 180 days after autologous stem cell transplantation.
Conditioning for the allogeneic transplant will consist of fludarabine and busulfan. Participants will receive tacrolimus and sirolimus as prophylaxis against graft versus host disease (GVHD).</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Incidence of Disease Relapse</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.2" lower_limit="7.5" upper_limit="30.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Two Year Progression Free Survival Rate for Participants Undergoing Both Autologous and Allogeneic Transplants</title>
        <time_frame>2 years after allogeneic transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Autologous Then Allogeneic Transplant</title>
            <description>All patients will receive conditioning with busulfan, etoposide, and cyclophosphamide (with mesna) and then will undergo autologous (auto) peripheral blood stem cell transplantation.
Patients will be re-evaluated after autologous transplant prior to proceeding to non-myeloablative allogeneic (allo) transplant. If eligible to proceed, allogenic transplantation will take place no earlier than 40 days and no later than 180 days after autologous stem cell transplantation.
Conditioning for the allogeneic transplant will consist of fludarabine and busulfan. Participants will receive tacrolimus and sirolimus as prophylaxis against graft versus host disease (GVHD).</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Two Year Progression Free Survival Rate for Participants Undergoing Both Autologous and Allogeneic Transplants</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72" lower_limit="55" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Two Year Overall Survival Rate for Participants Undergoing Both Autologous and Allogeneic Transplants</title>
        <time_frame>Two-years after Allogeneic Transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Autologous Then Allogeneic Transplant</title>
            <description>All patients will receive conditioning with busulfan, etoposide, and cyclophosphamide (with mesna) and then will undergo autologous (auto) peripheral blood stem cell transplantation.
Patients will be re-evaluated after autologous transplant prior to proceeding to non-myeloablative allogeneic (allo) transplant. If eligible to proceed, allogenic transplantation will take place no earlier than 40 days and no later than 180 days after autologous stem cell transplantation.
Conditioning for the allogeneic transplant will consist of fludarabine and busulfan. Participants will receive tacrolimus and sirolimus as prophylaxis against graft versus host disease (GVHD).</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Two Year Overall Survival Rate for Participants Undergoing Both Autologous and Allogeneic Transplants</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89" lower_limit="74" upper_limit="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Two Year Progression Free Survival Rate for All Participants</title>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Autologous Then Allogeneic Transplant</title>
            <description>All patients will receive conditioning with busulfan, etoposide, and cyclophosphamide (with mesna) and then will undergo autologous (auto) peripheral blood stem cell transplantation.
Patients will be re-evaluated after autologous transplant prior to proceeding to non-myeloablative allogeneic (allo) transplant. If eligible to proceed, allogenic transplantation will take place no earlier than 40 days and no later than 180 days after autologous stem cell transplantation.
Conditioning for the allogeneic transplant will consist of fludarabine and busulfan. Participants will receive tacrolimus and sirolimus as prophylaxis against graft versus host disease (GVHD).</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Two Year Progression Free Survival Rate for All Participants</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64" lower_limit="50" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Two Year Overall Survival Rate for All Participants</title>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Autologous Then Allogeneic Transplant</title>
            <description>All patients will receive conditioning with busulfan, etoposide, and cyclophosphamide (with mesna) and then will undergo autologous (auto) peripheral blood stem cell transplantation.
Patients will be re-evaluated after autologous transplant prior to proceeding to non-myeloablative allogeneic (allo) transplant. If eligible to proceed, allogenic transplantation will take place no earlier than 40 days and no later than 180 days after autologous stem cell transplantation.
Conditioning for the allogeneic transplant will consist of fludarabine and busulfan. Participants will receive tacrolimus and sirolimus as prophylaxis against graft versus host disease (GVHD).</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Two Year Overall Survival Rate for All Participants</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" lower_limit="70" upper_limit="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Two Year Progression Free Survival Rate for Participants Undergoing Only Autologous Transplant</title>
        <time_frame>Two Years</time_frame>
        <population>Participants who ONLY underwent Autologous transplant (did not proceed to Allogeneic)</population>
        <group_list>
          <group group_id="O1">
            <title>Autologous Then Allogeneic Transplant</title>
            <description>All patients will receive conditioning with busulfan, etoposide, and cyclophosphamide (with mesna) and then will undergo autologous (auto) peripheral blood stem cell transplantation.
Patients will be re-evaluated after autologous transplant prior to proceeding to non-myeloablative allogeneic (allo) transplant. If eligible to proceed, allogenic transplantation will take place no earlier than 40 days and no later than 180 days after autologous stem cell transplantation.
Conditioning for the allogeneic transplant will consist of fludarabine and busulfan. Participants will receive tacrolimus and sirolimus as prophylaxis against graft versus host disease (GVHD).</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Two Year Progression Free Survival Rate for Participants Undergoing Only Autologous Transplant</title>
          <population>Participants who ONLY underwent Autologous transplant (did not proceed to Allogeneic)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46" lower_limit="23" upper_limit="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Two Year Overall Survival Rate for Participants Undergoing Only Autologous Transplant</title>
        <time_frame>two years</time_frame>
        <population>Participants who ONLY underwent Autologous transplant, did not proceed to Allogeneic transplant</population>
        <group_list>
          <group group_id="O1">
            <title>Autologous Then Allogeneic Transplant</title>
            <description>All patients will receive conditioning with busulfan, etoposide, and cyclophosphamide (with mesna) and then will undergo autologous (auto) peripheral blood stem cell transplantation.
Patients will be re-evaluated after autologous transplant prior to proceeding to non-myeloablative allogeneic (allo) transplant. If eligible to proceed, allogenic transplantation will take place no earlier than 40 days and no later than 180 days after autologous stem cell transplantation.
Conditioning for the allogeneic transplant will consist of fludarabine and busulfan. Participants will receive tacrolimus and sirolimus as prophylaxis against graft versus host disease (GVHD).</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Two Year Overall Survival Rate for Participants Undergoing Only Autologous Transplant</title>
          <population>Participants who ONLY underwent Autologous transplant, did not proceed to Allogeneic transplant</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69" lower_limit="43" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Until 30 months after allogeneic transplant.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Autologous Then Allogeneic Transplant</title>
          <description>All patients will receive conditioning with busulfan, etoposide, and cyclophosphamide (with mesna) and then will undergo autologous (auto) peripheral blood stem cell transplantation.
Patients will be re-evaluated after autologous transplant prior to proceeding to non-myeloablative allogeneic (allo) transplant. If eligible to proceed, allogenic transplantation will take place no earlier than 40 days and no later than 180 days after autologous stem cell transplantation.
Conditioning for the allogeneic transplant will consist of fludarabine and busulfan. Participants will receive tacrolimus and sirolimus as prophylaxis against graft versus host disease (GVHD).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death, not otherwise specified</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Adult Respiratory Distress Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>colitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>mucositis oral</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>edema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>weight loss</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>muscle weakness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Yi-Bin Chen, MD</name_or_title>
      <organization>Mass General Hospital</organization>
      <phone>617-726-5765</phone>
      <email>ychen6@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

